Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2017–2018 · research · Clinical
Phase I clinical trials of a novel neurotrophic activator drug to treat Alzheimer's disease
Leen Kawas · Athira Pharma Inc.
2017–2019 · research · Biomarkers
Neurally-derived exosomes for the diagnosis and staging of sporadic Alzheimer's disease
Dennis Selkoe · Brigham and Women's Hospital
2017–2020 · research · Drug Discovery
A potent lipoxin analogue as a potential treatment for Alzheimer's disease
Masashi Kitazawa · University of California, Irvine
2017–2019 · research · Drug Discovery
Therapeutic Potential of Dual Leucine Zipper Kinase Inhibitors in Alzheimer's Disease
William Ray · The University of Texas MD Anderson Cancer Center
2017–2021 · research · Biomarkers
Imaging [18F] AV-1451 and [18F] AV-45 in acute and chronic traumatic brain injury - Add On Funding
Sam Gandy · Icahn School of Medicine at Mount Sinai
2017–2020 · research · Clinical
Phase II Study to Assess Safety and Target Engagement in AMYX0035 in AD
Kent Leslie · Amylyx Pharmaceuticals, Inc.
2017–2018 · research · Clinical
Benfotiamine in Alzheimer's Disease: A Pilot Study
Gary Gibson · Winifred Masterson Burke Medical Research Institute
2016–2017 · research · Biomarkers
The utility of cFLIP and MCL 1 and their regulatory microRNAs as novel biomarkers of Alzheimer's disease
Gerard Nuovo · Gnome Diagnostics, Llc.
2016–2017 · research · Drug Discovery
Preclinical safety and toxicology of NTRX-07 (formerly MDA7)
Joseph Foss · Neurotherapia, Inc.
2016–2017 · research · Drug Discovery
Protein disulfide isomerase (PDI) inhibitors as neuroprotective agents for Alzheimer's disease.
Brent Stockwell · Trustees Of Columbia University In The City Of New York
2016–2018 · research · Clinical
Therapeutic Effects of Nilotinib in Alzheimer's Disease Patients
Raymond Turner · Georgetown University
2016–2018 · research · Clinical
Brain Health Registry Trial-Ready Cohort
Michael Weiner · University of California, San Francisco
2016–2017 · research · Drug Discovery
Lead Optimization and Pre-Clinical Development of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
Milton Greenberg · Vivreon Biosciences, Llc
2016–2024 · research · Clinical
Low-dose lithium for the treatment of behavioral symptoms in FTD
Edward Huey · Brown University
2016–2018 · research · Drug Discovery
Development of Klotho Enhancers as Novel Therapeutics for AD (Bridge Funding)
Carmela Abraham · Boston University
2016–2018 · research · Drug Discovery
Chiral Switching and Drug Repurposing: Evaluation of (R)-Ricobendazole in the Tau mouse model (rTG4510) of AD
Kevin Hodgetts · The Laboratory For Drug Discovery In Neurodegeneration
2016–2017 · research · Drug Discovery
Drug development and optimization of compounds stabilizing ryanodine calcium channels for AD
Grace Stutzmann · Rfums/chicago Medical School
2016–2020 · research · Clinical
Cholesterol-metabolizing enzyme CYP46A1 as a new therapeutic target for Alzheimer's disease
Irina Pikuleva · Case Western Reserve University
2016–2021 · research · Biomarkers
The Role of Perfusion MRI in Improving the Diagnosis of FTD Subtypes and Longitudinal Monitoring of Disease Progression
Keith St Lawrence · Lawson Health Research Institute
2016–2017 · research · Clinical
BPN14770 Safety and Cognitive Benefit in Young and Elderly Subjects
Mark Gurney · Tetra Therapeutics Inc.
2016–2017 · research · Drug Discovery
NeuroRestore - development of positive allosteric modulators of TrkA and TrkB
Pontus Forsell · Alzecure Pharma Ab
2016–2017 · conference · Conferences/Other
Building an Infrastructure to Support FTLD Therapeutic Development
Nadine Tatton · Association for Frontotemporal Degeneration
2016 · research · Drug Discovery
Therapeutic potential of palmitoylethanolamide in a transgenic animal model of Alzheimer's disease: focus on neuroinflammation and synaptic dysfunction.
Luca Ferraro · University of Ferrara
2016–2017 · research · Biomarkers
Translation of an optimized PET radiopharmaceutical for imaging tau pathology in Alzheimer's patients
Neil Vasdev · Massachusetts General Hospital (p)
2016–2017 · research · Biomarkers
Quantitation of TDP-43 isoforms in CSF by mass spectrometry
Mari Demarco · University of British Columbia
2016–2017 · research · Drug Discovery
VGF peptide delivery for the suppression of memory impairment in an Alzheimer's disease model
Stephen Salton · Icahn School of Medicine at Mount Sinai
2016–2018 · research · Drug Discovery
FAAH Inhibitors as Alzheimer's Disease Medications (2nd year continuation)
Alexandros Makriyannis · Northeastern University
2016–2017 · prize · Drug Discovery
2015 Goodes Prize for Excellence in Alzheimer's Drug Discovery: IND-Enabling Development of Small Molecule TrkB Ligands for Alzheimer's Therapeutics
Frank Longo · Pharmatrophix
2016–2017 · conference · Conferences/Other
NEURODEGENERATION: From Cellular Concepts to Clinical Applications
Huda Zoghbi · Baylor College Of Medicine (p)
2016–2021 · research · Clinical
Phase 1 First-in-Human Multiple Ascending Dose Study of the Putative Cognitive Enhancer and M1 Positive Allosteric Modulator VU0467319
Paul Newhouse · Vanderbilt University
2016–2017 · research · Drug Discovery
Discovery and preclinical development of isoform selective JNK inhibitors for Alzheimer's disease
Sung Ok Yoon · The Ohio State University
2016–2022 · research · Clinical
Effect of candesartan on prodromal Alzheimer's Disease and its related biomarkers
Ihab Hajjar · Emory University
2016–2017 · research · Drug Discovery
Identification of small molecules that modulate microglia/macrophage uptake in primary human cells
Elizabeth Bradshaw · Brigham and Women's Hospital
2016 · research · Drug Discovery
EP2 antagonists for the suppression of inflamnation and neuropathology in Alzheimer's model - Year 2 [Add-On Funding]
Thota Ganesh · Emory University
2016–2018 · research · Biomarkers
Epigenetic mechanisms in human memory: quantification by non-invasive PET imaging in the aged brain
Jacob Hooker · Massachusetts General Hospital (p)
2016–2017 · research · Drug Discovery
Humanization of a First-in-Class Anti-Inflammatory for Alzheimer's Disease Therapy
Danna B. Zimmer · University of Maryland, College Park
2016–2018 · research · Prevention
Targeting older adults for blood pressure interventions
Lenore Launer · National Institute on Aging
2016–2019 · research · Drug Discovery
Treatment strategies based on enhancing dopamine release from noradrenergic axons.
John Lisman · Brandeis University
2016–2017 · research · Drug Discovery
Inhibiting Neutrophil Extracellular Trap (NET) formation as a novel therapeutic approach to Alzheimer's disease
Paul Thompson · University of Massachusetts Boston
2016–2017 · research · Drug Discovery
Testing of selective DYRKIA inhibitors as a novel treatment for AD
Travis Dunckley · Asu Foundation For A New American University